Group One Trading, L.P. Akebia Therapeutics, Inc. Transaction History

Group One Trading, L.P.

$2.54 Billion
Q4 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $11,567 - $19,074	12,306 New	12,306 $16,000
Q1 2024 May 10, 2024	SELL	$1.27 - $2.24 $36,866 - $65,024	-29,029 Reduced 58.4%	20,678 $37,000
Q4 2023 Feb 14, 2024	SELL	$0.8 - $1.28 $30,955 - $49,528	-38,694 Reduced 43.77%	49,707 $61,000
Q3 2023 Nov 09, 2023	SELL	$0.87 - $1.84 $68,556 - $144,993	-78,801 Reduced 47.13%	88,401 $100,000
Q2 2023 Aug 09, 2023	SELL	$0.51 - $1.43 $50,013 - $140,232	-98,065 Reduced 36.97%	167,202 $153,000
Q1 2023 May 12, 2023	SELL	$0.56 - $1.15 $59,791 - $122,786	-106,771 Reduced 28.7%	265,267 $148,000
Q4 2022 Feb 09, 2023	SELL	$0.25 - $0.58 $10,168 - $23,591	-40,675 Reduced 9.86%	372,038 $215,000
Q3 2022 Nov 09, 2022	SELL	$0.3 - $0.46 $16,575 - $25,415	-55,251 Reduced 11.81%	412,713 $131,000
Q2 2022 Aug 11, 2022	BUY	$0.32 - $0.67 $21,049 - $44,072	65,780 Added 16.36%	467,964 $165,000
Q1 2022 May 12, 2022	BUY	$0.72 - $2.93 $242,483 - $986,774	336,783 Added 514.95%	402,184 $289,000
Q4 2021 Feb 11, 2022	BUY	$2.26 - $3.34 $100,723 - $148,857	44,568 Added 213.93%	65,401 $148,000
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.88 $8,152 - $13,459	3,469 Added 19.98%	20,833 $60,000
Q2 2021 Aug 10, 2021	SELL	$2.83 - $4.2 $101,959 - $151,317	-36,028 Reduced 67.48%	17,364 $66,000
Q1 2021 May 12, 2021	SELL	$2.92 - $5.06 $120,514 - $208,836	-41,272 Reduced 43.6%	53,392 $181,000
Q4 2020 Feb 10, 2021	BUY	$2.22 - $3.78 $133,386 - $227,117	60,084 Added 173.75%	94,664 $265,000
Q3 2020 Nov 12, 2020	BUY	$2.39 - $13.08 $82,646 - $452,306	34,580 New	34,580 $87,000
Q2 2020 Aug 13, 2020	SELL	$6.67 - $13.58 $560,093 - $1.14 Million	-83,972 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$4.1 - $10.24 $81,713 - $204,083	19,930 Added 31.12%	83,972 $637,000
Q4 2019 Feb 10, 2020	SELL	$3.16 - $6.73 $12,671 - $26,987	-4,010 Reduced 5.89%	64,042 $405,000
Q3 2019 Nov 12, 2019	SELL	$3.55 - $5.4 $7,188 - $10,935	-2,025 Reduced 2.89%	68,052 $267,000
Q2 2019 Aug 09, 2019	BUY	$4.1 - $8.05 $287,315 - $564,119	70,077 New	70,077 $339,000
Q1 2019 May 13, 2019	SELL	$5.41 - $8.73 $44,048 - $71,079	-8,142 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$5.39 - $9.15 $26,443 - $44,889	-4,906 Reduced 37.6%	8,142 $45,000
Q3 2018 Nov 08, 2018	BUY	$7.44 - $10.65 $9,672 - $13,845	1,300 Added 11.07%	13,048 $115,000
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $107,494 - $133,222	11,748 New	11,748 $117,000
Q4 2017 Feb 09, 2018	SELL	$14.24 - $19.59 $81,353 - $111,917	-5,713 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$13.06 - $19.67 $74,611 - $112,374	5,713	5,713 $112,000

Others Institutions Holding AKBA

# of Institutions

128

Shares Held

63.3M

Call Options Held

50.6K

Put Options Held

203K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $450M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account